Download presentation
Presentation is loading. Please wait.
Published byMichael Haraway Modified over 10 years ago
1
TB GUIDELINE AND MANAGEMENT DR.JUSLEE DOUSIN
2
TB STORY TB induced skeletal defects as early as 8000BC Hippocrates called it “phthisis” in 460BC (coughing out blood)
3
St Louis curing TB, “The King touches you, God heal you” Henri IV touching TB
4
19th Century: The enemy identified Dr Robert Koch’s discovery of the bacillus in 1882 TB ravages Europe/America
6
1944 Medicine success Streptomycin discovered Albert CALMETTE & Camille GUERIN
7
1948 WHO Enters Recognized inadequate treatment and MDRTb WHO declares TB a global Emergency in 1993 1999 WHO declares a TB crisis in the Western Pacific Region
8
THE 21ST CENTURY TIME BOMB
9
Diagnosis of Tuberculosis History and clinical finding Microbiology Serology Chest x-ray Biopsy
10
1. History and examination Fever LOA.LOW Night sweats Cough >2/52 Haemoptysis Hoarseness of voice Contact
11
2.Microbiology Sputum AFB/AFB C+S Most cost effective method Categorization for treatment
13
3. Serology Mantoux Test Antibody/antigen PCR
14
4.CXR 95% apicoposterior of an upper lobe chronicity Cavity ( 1 cavity= 1 million bacilli),40- 80% cases Miliary Effusion fibrosis Major finding:
16
Activity: Active-soft consolidation -cavity with thick & irregular wall -adenopathy +sequale -pleural effusion size Intermediate-Tuberculoma margin calcification Inactive-normal -fibrosis,small well defined nodules, calcified, -stable x-ray
17
Radiological Classification Minimal –Slight lesion, no cavity, total volume less then that above the second costosternal junction Advanced –Total lesion not exceeding one lung volume –Cavity not more then 4 cm (total) Far advanced –More extensive lesions then above
18
4. Biopsy of Tissue Fine Needle aspiration Pleural biopsy Trucut biopsy Excision biopsy
19
Classification of TB Pulmonary TB –Sputum +ve, -ve Extrapulmonary TB Pulmonary and extrapulmonary TB
20
Case Definitions New case Relapse case Treatment failure Treatment after interruption Chronic case Transferred in case Defaulter
21
New case A patient who has never had treatment for TB or who has taken antiTB drugs for less than four weeks
22
Relapse case Sputum positive relapse is a patient who was cured for any form of TB in the past after a full course of treatment and has become sputum smear positive Sputum negative relapse is a patient who has been cured any form of TB in the past and has developed active disease based on bacteriological, histology or clinicoradiological
23
Treatment failure A patient who, while on treatment, remained or became again smear positive five months or later after commencing treatment. It is also a patient who was initially smear negative before starting treatment and has become smear positive after the second month of treatment
24
Treatment after interruption A patient who interrupts treatment for two months or more and returns to the health service with smear positive sputum or active disease judged by clinico-radiological evidence
25
Chronic case A patient who remained or became again smear positive after completing a fully supervised re-treatment regimen
26
Transferred in case Transferred in from another centre for continuation of TB treatment. The transferred centre undertakes the responsibility of continuing to treat the patient and supervising progress.
27
Defaulter A patient who has missed more than 25% of the treatment doses in one month I.e more than 6 doses of daily treatment or more than 2 doses of biweekly treatment
28
Treatment categories Category I –New case Category II –Relapse –Treatment failure –Treatment after interruption Category III –Chronic case
29
AIMS OF TREATMENT To cure patient To prevent death To prevent relapse To decrease transmission to others
30
Tuberculosis Drugs
31
Duration Intensive phase –Three or four drugs given daily for two or three months e.g. 2EHRZ,2SHRZ,2RHZ Continuation phase –Two or three drugs given intermittently for four months or more e.g. 4H 2 R 2 or 4S 2 H 2 R 2 or 4HR or 4H 3 R 3 or 4 S 3 H 3 R 3
32
Patient Monitoring Baseline Investigations- LFT/FBC/BUSE/RBS/Sr.Uric Acid/Sr.Creatinine CXR during follow-up Sputum AFB every 2 months Culture when required
33
Patients Supervision DOTS FOR ALL PATIENTS
34
Advantages of DOTS Integration with primary health care Reduced hospitalisation Prevents MDR TB
35
SIDE EFFECTS:
36
Advise to all patients Education on TB and Rx Educate family Motivation during follow-up Ensure DOTS Prompt defaulter tracing Socio-economic help
37
Category I Intensive phase: 2SHRZ or 2EHRZ or 2 HRZ for two months Continuation phase : 4H 2 R 2 or 4S 2 H 2 R 2 or 4HR or 4H 3 R 3 or 4 S 3 H 3 R 3. Duration can be extended for severe forms of extrapulmonary TB or TB in HIV patients
38
Category II Send MTB culture and sensitivity Do not initiate standard treatment Refer to Chest Physician or physician in charge of chest clinic Subsequent drug regimen based on sensitivity results and clinical response
39
Category III Send MTB C&S Refer to chest physician or physician in charge of chest clinic.
40
Tuberculosis in special situation Children Renal impairment Liver impairment Pregnancy HIV Extrapulmonary
41
TB in children HRZ/HR Daily for six months Omit streptomycin Ethambutol with decreased dose
42
TB and Renal impairment Omit Streptomycin Ethambutol with decreased dose Both excreted by kidney Longer duration 2HRZ/6HR safe
43
TB and liver disease Omit PZA Omit rifampicin 2SHRE/7H 2 R 2 2SHE/10HE 2SH/12S 2 H 2 3SE/6HR in acute hepatitis (avoid treatment until hepatitis resolved)
44
TB in pregnancy/lactation Avoid streptomycin Standard treatment Normal dosages TB prophylaxis if mother sputum positive during lactation TB and OCP Rifampicin interats with OCP Increase oestrogen dosage or change contraception
45
TB and HIV 2HRZ/7H2R2 or six months after cultures are negative 2REZ/12RE if INH resistance 18EHZ if rifampicin resistance Avoid streptomycin Low doses in ill patients Monitor side effects closely Longer duration DOTS
46
TB FIGHT POVERTY
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.